Teva Pharmaceutical Industries (NYSE:TEVA) Shares Gap Down – Should You Sell?

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $16.75, but opened at $16.22. Teva Pharmaceutical Industries shares last traded at $16.56, with a volume of 634,057 shares changing hands.

Wall Street Analyst Weigh In

Several equities analysts have commented on TEVA shares. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Finally, UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Stock Performance

The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The business’s 50 day moving average price is $17.84 and its two-hundred day moving average price is $17.20.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Large investors have recently bought and sold shares of the company. Oppenheimer & Co. Inc. raised its stake in shares of Teva Pharmaceutical Industries by 9.6% during the first quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock valued at $191,000 after acquiring an additional 1,180 shares during the last quarter. Sei Investments Co. raised its position in Teva Pharmaceutical Industries by 0.9% during the 1st quarter. Sei Investments Co. now owns 457,322 shares of the company’s stock worth $6,453,000 after purchasing an additional 4,000 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in Teva Pharmaceutical Industries by 13.4% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,018 shares of the company’s stock worth $875,000 after buying an additional 7,335 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Teva Pharmaceutical Industries by 36.3% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,691 shares of the company’s stock valued at $8,857,000 after buying an additional 167,097 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Teva Pharmaceutical Industries by 3.5% in the first quarter. Vanguard Group Inc. now owns 825,537 shares of the company’s stock valued at $11,648,000 after buying an additional 28,071 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.